Press Releases

Press Releases

View all news
Voronoi Signs License-Out Option Agreement with U.S. Biotech ANVIA
2024.08.26
⚫ Acquires 2.5 million ANVIA shares by granting an option on VRN04 development rights
⚫ ANVIA, a biotech founded by Deerfield to develop therapies for chronic inflammatory and autoimmune diseases

Voronoi (KOSDAQ 310210) announced on the 26th that it has signed an agreement with Anvia Therapeutics, Inc. of the U.S. ("Anvia").
The agreement grants Anvia an exclusive option to acquire Voronoi's pipeline program VRN04. Anvia is a U.S. biotech founded by Deerfield that develops a pipeline of small-molecule therapies for chronic inflammatory and autoimmune diseases.
Under the agreement, Voronoi receives 2.5 million shares of Anvia common stock as an upfront payment, and Anvia will additionally provide the funding required to derive the final drug candidate for VRN04. In the future, if Anvia exercises its option to acquire VRN04, Voronoi will receive additional equity and cash under the transfer agreement. Daekwon Kim, CEO of the Research Division of Voronoi, said, "We have high expectations for Anvia in the development of an orally administered RIPK1 therapy for autoimmune diseases." Hyuntae Kim, CEO of the Management Division of Voronoi, added, "We are pleased to announce the agreement with Anvia. We will continue to collaborate with U.S. biotech companies founded by leading U.S. healthcare investors such as Deerfield in order to develop new drugs in areas where, as in this case, no therapy exists."